LT2000081A - Core tablet for controlled release of gliclazide after oral administration - Google Patents

Core tablet for controlled release of gliclazide after oral administration

Info

Publication number
LT2000081A
LT2000081A LT2000081A LT2000081A LT2000081A LT 2000081 A LT2000081 A LT 2000081A LT 2000081 A LT2000081 A LT 2000081A LT 2000081 A LT2000081 A LT 2000081A LT 2000081 A LT2000081 A LT 2000081A
Authority
LT
Lithuania
Prior art keywords
gliclazide
oral administration
controlled release
core tablet
release
Prior art date
Application number
LT2000081A
Other languages
Lithuanian (lt)
Other versions
LT4932B (en
Inventor
Bruno Huet-De-Barochez
Patrick Wuthrich
Louis Martin
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Priority to LT2000081A priority Critical patent/LT4932B/en
Publication of LT2000081A publication Critical patent/LT2000081A/en
Publication of LT4932B publication Critical patent/LT4932B/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to core tablet for controlled release of gliclazide providing continuous and monotonous release of active substance which is insensitive for pH change values in solution media after oral administration.
LT2000081A 2000-08-29 2000-08-29 Core tablet for controlled release of gliclazide after oral administration LT4932B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LT2000081A LT4932B (en) 2000-08-29 2000-08-29 Core tablet for controlled release of gliclazide after oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2000081A LT4932B (en) 2000-08-29 2000-08-29 Core tablet for controlled release of gliclazide after oral administration

Publications (2)

Publication Number Publication Date
LT2000081A true LT2000081A (en) 2002-03-25
LT4932B LT4932B (en) 2002-07-25

Family

ID=19721487

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000081A LT4932B (en) 2000-08-29 2000-08-29 Core tablet for controlled release of gliclazide after oral administration

Country Status (1)

Country Link
LT (1) LT4932B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346709A (en) 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier

Also Published As

Publication number Publication date
LT4932B (en) 2002-07-25

Similar Documents

Publication Publication Date Title
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ES2172239T3 (en) OSMOTIC SYSTEM OF LIBERATION OF PHARMACOS.
LTC1345910I2 (en) CHINAZOLIDINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THOSE COMPOUNDS, THEIR USES AND METHOD OF THEIR PREPARATION
DZ3358A1 (en) PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURE INHALER-DOSERS
EP1286662A4 (en) Tablets and methods for modified release of hydrophilic and other active agents
AU2001286940A1 (en) Drug delivering prostheses and methods of use
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EE05149B1 (en) Biar acarboxamides, process for their preparation, pharmaceutical composition containing them and their use in therapy
EE05001B1 (en) Heterocyclic compounds, process for their preparation, pharmaceutical composition containing them and their use in therapy
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
GB0017060D0 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
ZA966163B (en) Novel galanthamine derivatives, process for the preparation thereof, their application as medical drugs, and pharmaceutical compositions containing said derivatives.
HUP9700806A2 (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine and process for the preparation thereof
HK1047548A1 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
LT2000081A (en) Core tablet for controlled release of gliclazide after oral administration
IL155819A0 (en) Methods of treatment comprising administration of substance p
NO20024823L (en) Medicinal preparations containing camptothecin derivative and pH regulating agent
AU2002220921A1 (en) Treatment of posterior capsule opacification
ZA200210361B (en) Method of administering bishosphonates.
LV12803B (en) Tablet matrix for prolonged release of gliclazide
JO2173B1 (en) Materix tablet enabling prolonged release of gliclazide after administration by the oral route.
GB0007788D0 (en) Method to evaluate the therapeutic and toxic effects related to drug administration
GB0008741D0 (en) Administration of beneficial substances
AU2001258852A1 (en) Model animals of daily fluctuations in blood pressure and urinary sodium

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20200829